Related Experiment Video

Updated: Aug 13, 2026

Tracking Mouse Bone Marrow Monocytes In Vivo
12:08

Tracking Mouse Bone Marrow Monocytes In Vivo

Published on: February 27, 2015

Haematopoietic malignancies in Côte d'Or (France): a population based study

P M Carli, C Milan, A Lange

    British Journal of Cancer
    |June 1, 1986
    PubMed

    Insights

    This study tracked haematopoietic malignancies in Côte d'Or, France. Incidence rates were notably high, especially for chronic lymphocytic leukaemia, with urban areas showing increased risk.

    Area of Science:

    • Epidemiology
    • Hematology
    • Public Health

    Background:

    • Haematopoietic malignancies represent a significant public health concern.
    • Accurate incidence data is crucial for understanding disease burden and trends.
    • Previous epidemiological data for these cancers in the Côte d'Or region was limited.

    Purpose of the Study:

    • To establish a registry for haematopoietic malignancies in Côte d'Or, France.
    • To determine the incidence and epidemiological characteristics of these diseases.
    • To compare findings with international registries.

    Main Methods:

    • A population-based registry was established in Côte d'Or on January 1, 1980.
    • Data was collected over a five-year period (1980-1984).
    • Incidence rates were calculated and age-standardized; risk factors like location were analyzed.

    Main Results:

    • 704 new cases of haematopoietic malignancies were recorded between 1980 and 1984.
    • Crude incidence rates were 32.7/100,000 for males and 24.9/100,000 for females.
    • Chronic lymphocytic leukaemia showed particularly high incidence rates, especially in males and urban populations.

    Conclusions:

    • The incidence of haematopoietic malignancies in Côte d'Or is among the highest reported globally.
    • Chronic lymphocytic leukaemia incidence is a significant finding in this registry.
    • Urban residence was associated with a higher risk of these malignancies.

    More Related Videos

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up09:01

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

    Published on: March 26, 2018

    Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation12:05

    Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

    Published on: November 3, 2018

    Related Concept Videos

    Cancers Originate from Somatic Mutations in a Single Cell02:21

    Cancers Originate from Somatic Mutations in a Single Cell

    Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
    Rous Sarcoma Virus (RSV) and Cancer01:03

    Rous Sarcoma Virus (RSV) and Cancer

    Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
    RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
    Cancers Originate from Somatic Mutations in a Single Cell02:21

    Cancers Originate from Somatic Mutations in a Single Cell

    Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Bone Marrow Sampling and Transplants01:22

    Bone Marrow Sampling and Transplants

    Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
    The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
    Cancer Survival Analysis01:21

    Cancer Survival Analysis

    Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...